MSC-PAN • RESEARCH USE ONLY

Insulin-Secreting Pancreatic Beta Cells

Fully differentiated beta cells that synthesize insulin in response to glucose. Functional beta cells derived from stem cells that produce and secrete insulin in response to glucose levels.

Glucose-responsive insulin
ISLET-LIKE PHYSIOLOGY
Fully differentiated beta cells that synthesize and secrete insulin in response to glucose — aimed at physiological glycemic regulation.
MSC priming prerequisite
AUTOIMMUNE CONTEXT
MSC priming infusion may blunt autoimmune attack before use — pairing immunomodulation with beta-cell replacement logic.
Endogenous restoration
THERAPEUTIC GOAL
Intended to restore pancreatic endocrine output and reduce or eliminate chronic exogenous insulin dependence when combined with supportive immune protocols.
ROUTES, FORMATS & APPLICATIONS
Routes
IM
Quantities
10 Million Cells2ml
25 Million Cells5ml
Potential Applications
  • Type 1 Diabetes (with prior MSC immune regulation)
  • Type 2 Diabetes (advanced insulin-dependency)
  • Maturity Onset Diabetes of the Young (MODY)
  • Islet Cell Dysfunction Post-Pancreatitis
  • Hypoglycemia Unawareness (supportive therapy)
  • Diabetic Nephropathy
  • Chronic Pancreatitis

Compliance · Stem cells

cGMP manufacturing & cryopreservation

Cells are manufactured under cGMP conditions and cryopreserved using a non-toxic, glucose-based method with greater than 98% viability.

cGMPNON-TOXIC CRYOPRESERVATION>98% VIABILITY
Viability & cryopreservation

Cryopreserved using a non-toxic, glucose-based method with greater than 98% viability.

GLUCOSE-BASED CRYO>98% VIABILITY

Explore More

Keep browsing our product lineup